Sage Therapeutics, Inc. (NASDAQ:SAGE) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On May9, 2017, Sage Therapeutics, Inc. announced its financial
results for the quarter ended March31, 2017. A copy of the press
release is being furnished as Exhibit 99.1 to this Report on Form
8-K.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or
the Exchange Act, except as expressly set forth by specific
reference in such filing.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 |
Press release issued by Sage Therapeutics, Inc. on May 9, 2017, furnished herewith. |
About Sage Therapeutics, Inc. (NASDAQ:SAGE)
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program. Sage Therapeutics, Inc. (NASDAQ:SAGE) Recent Trading Information
Sage Therapeutics, Inc. (NASDAQ:SAGE) closed its last trading session down -2.19 at 66.03 with 382,887 shares trading hands.
